STOCK TITAN

PGA Champion Jason Day Launches Getting Out of the Rough Video Series With AstraZeneca to Support Lung Cancer Biomarker Testing Awareness

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

AstraZeneca, in collaboration with PGA Champion Jason Day, launched the Getting Out of the Rough campaign to raise awareness about the importance of biomarker testing for lung cancer diagnosis. The campaign features a six-episode video series that includes discussions with experts and celebrities, emphasizing how biomarker testing can guide treatment plans. Day's personal experience with his mother's lung cancer diagnosis highlights the need for comprehensive testing. The first episode premiered on April 4, 2022. For more information, visit www.diagnosisstories.com.

Positive
  • Launch of the Getting Out of the Rough campaign may enhance brand reputation.
  • Increased public awareness of biomarker testing could lead to better patient outcomes.
Negative
  • None.

Campaign aims to increase understanding of the role of biomarker testing to complete a lung cancer diagnosis

WASHINGTON, April 4, 2022 /PRNewswire/ -- Jason Day, pro-golfer and PGA Champion, joins AstraZeneca to launch the Getting Out of the Rough campaign, aimed to educate lung cancer patients and their caregivers about biomarker testing and the importance of completing a lung cancer diagnosis through this approach. The Getting Out of the Rough campaign features a six-episode video series, where Jason is joined by friends from the worlds of medicine and entertainment to discuss and learn about adapting after you or someone you love has been diagnosed with lung cancer. Among the group is Modern Family star Julie Bowen, whose series episode premiered today, as well as actors Anthony Anderson and Bellamy Young, happiness expert Shawn Achor, oncologist Dr. Mark Socinski and Jason's wife, Ellie Day.

Jason Day, pro-golfer and PGA Champion, joins AstraZeneca to launch the Getting Out of the Rough campaign. 

Jason's mother, Dening, was diagnosed with Stage IV non-small cell lung cancer (NSCLC), in 2017. Jason immediately stepped into the roles of caregiver and advocate to ensure that she received the best care possible—which for Dening included access to comprehensive biomarker testing. Biomarker testing can help reveal information about your specific type of lung cancer. This will help you and your healthcare team determine your treatment plan. Although Dening passed away in March 2022, she was able to spend extended time with her family— the extra time that Jason's wife Ellie refers to as a "silver lining."

"I'm honored to be launching the Getting Out of the Rough campaign. The issue of lung cancer and biomarker testing is deeply personal to me. When my mother was diagnosed with Stage IV lung cancer, we felt hopeless and did not know what kinds of treatment options existed at the time, nor what would work best for her," said Jason Day. "It wasn't until her healthcare team suggested comprehensive biomarker testing that suddenly new treatment options quickly became possible. Before my mom's diagnosis, I had never heard of biomarker testing or targeted therapy."

To help share information about Getting Out of the Rough, Jason is joined by medical oncologist and lung cancer specialist, Dr. Mark Socinski, who specializes in non-small cell and small-cell lung cancer. In their episode, Dr. Socinski speaks with Jason on the importance of having a well-thought-out treatment plan and how to work with your healthcare team to discuss all your options when faced with a lung cancer diagnosis.

"Just like golf is about aiming for a specific target, comprehensive biomarker testing can help you and your doctor get a complete diagnosis and determine the best path forward for treatment of lung cancer," said Dr. Socinski. "Today, we have several drugs that target these biomarkers, but you can't use the drugs appropriately unless you find the target. That's why I encourage all my patients to consider comprehensive biomarker testing."

To learn more about Getting Out of the Rough and watch episode 1, please visit www.diagnosisstories.com.

About Getting Out of the Rough

Getting Out of the Rough encourages lung cancer patients and caregivers to obtain a complete diagnosis through comprehensive biomarker testing. For more information on Getting Out of the Rough, visit www.diagnosisstories.com.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/pga-champion-jason-day-launches-getting-out-of-the-rough-video-series-with-astrazeneca-to-support-lung-cancer-biomarker-testing-awareness-301517014.html

SOURCE AstraZeneca

FAQ

What is the purpose of the Getting Out of the Rough campaign by AstraZeneca?

The campaign aims to educate lung cancer patients and caregivers about the importance of biomarker testing for accurate diagnosis and treatment options.

Who is involved in the Getting Out of the Rough campaign?

PGA Champion Jason Day, along with medical experts and celebrities, is featured in the campaign.

When was the Getting Out of the Rough campaign launched?

The campaign was launched on April 4, 2022.

What does biomarker testing help with in lung cancer treatment?

Biomarker testing helps identify specific types of lung cancer, enabling healthcare teams to create tailored treatment plans.

Where can I find more information about the Getting Out of the Rough campaign?

More information can be found at www.diagnosisstories.com.

AstraZeneca PLC

NASDAQ:AZN

AZN Rankings

AZN Latest News

AZN Stock Data

205.55B
3.10B
0.01%
16.76%
0.24%
Drug Manufacturers - General
Healthcare
Link
United States of America
Cambridge